CNTX
CONTEXT THERAP (CNTX)
NASDAQ
$2.09-$0.33 (-13.84%)
Price as of Jun 03, 2026 7:55 PM EDT
  • $261.9M
    Market Cap
  • 315.81%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Income Statement
Total Operating Revenue
N/A
N/A
N/A
N/A
1.2M
+112.69%
547,268
N/A
Cost of Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Gross Profit
0
N/A
0
-100.00%
1.2M
+112.69%
547,268
N/A
Sales and Marketing Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Research and Development Expense
-31.9M
+40.33%
-22.7M
+27.66%
-17.8M
+134.26%
-7.6M
+10.13%
Depreciation and Amortization Expense
16,251
+49.35%
10,881
-9.66%
12,044
+29.95%
9,268
N/A
Total Operating Expenses
7.8M
+8.64%
7.2M
-0.92%
7.3M
-6.42%
7.8M
+114.43%
Operating Profit
-39.7M
+32.68%
-29.9M
+19.35%
-25.1M
+63.01%
-15.4M
+46.13%
Interest Income
3.4M
+5.57%
3.2M
N/A
N/A
N/A
N/A
N/A
Interest Expense
N/A
N/A
N/A
N/A
N/A
N/A
-46,000
-28.39%
Interest Income and Expense and Net
3.4M
+5.57%
3.2M
N/A
0
+100.00%
-46,000
-28.39%
Total Nonoperating Income and Expense
200,471
+14,138.59%
-1,428
-97.43%
-55,570
+2,672.95%
-2,004
-101.62%
Income before Taxes
-39.7M
+32.68%
-29.9M
+19.35%
-25.1M
+63.01%
-15.4M
+46.13%
Income Taxes
0
N/A
0
N/A
0
N/A
0
N/A
Extraordinary Items
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
-36.1M
+35.17%
-26.7M
+11.52%
-24.0M
+61.53%
-14.8M
+41.88%
Net Income from Continuing Operations Applicable to Common
-36.1M
+35.17%
-26.7M
+11.52%
-24.0M
+61.53%
-14.8M
+41.88%
Basic EPS and Net Income
-0.38
-17.39%
-0.46
-69.33%
-1.50
+61.29%
-0.93
-74.80%
Diluted EPS and Net Income
-0.38
-17.39%
-0.46
-69.33%
-1.50
+61.29%
-0.93
-74.80%
Basic Weighted Average Shares
95.2M
+62.94%
58.4M
+265.88%
16.0M
0.00%
16.0M
+463.44%
Diluted Weighted Average Shares
95.2M
+62.94%
58.4M
+265.88%
16.0M
0.00%
16.0M
+463.44%
Balance Sheet
Cash and Cash Equivalents
66.0M
-30.11%
94.4M
+553.50%
14.4M
-59.29%
35.5M
-28.48%
Short-Term Investments
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
66.0M
-30.11%
94.4M
+553.50%
14.4M
-59.29%
35.5M
-28.48%
Total Current Assets
68.4M
-30.18%
97.9M
+510.05%
16.0M
-57.61%
37.9M
-26.15%
Accumulated Depreciation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Property and Plant and Equipment and Net
29,656
+147.98%
11,959
-22.96%
15,524
-43.69%
27,568
N/A
Total Long-Term Assets
29,656
+147.98%
11,959
N/A
0
-100.00%
32,750
N/A
Total Assets
68.5M
-30.20%
98.1M
+510.90%
16.1M
-57.69%
38.0M
-26.00%
Income Taxes Payable
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Short-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Current Liabilities
8.0M
+191.80%
2.7M
-34.43%
4.2M
+30.68%
3.2M
+5.74%
Total Long-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
5.7M
N/A
Total Long-Term Liabilities
0
-100.00%
112,064
N/A
N/A
N/A
55,000
N/A
Total Liabilities
8.0M
+180.37%
2.9M
-31.76%
4.2M
+30.68%
3.2M
+5.74%
Retained Earnings
-130.9M
+38.11%
-94.8M
+39.27%
-68.1M
+54.35%
-44.1M
+50.71%
Total Stockholders Equity
60.5M
-36.52%
95.3M
+702.51%
11.9M
-65.85%
34.8M
-28.00%
Total Shares Outstanding
91.9M
+2.42%
89.7M
+461.84%
16.0M
0.00%
16.0M
0.00%
Cash Flow
Cash from Operating Activities
-26.4M
+81.26%
-14.6M
-30.84%
-21.0M
+55.34%
-13.5M
+53.98%
Capital Expenditures
33,948
+364.02%
7,316
N/A
0
-100.00%
36,836
N/A
Cash from Investing Activities
-2.0M
-86.22%
-14.8M
N/A
0
+100.00%
-536,836
+114.73%
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
-15,268
-100.01%
109.3M
N/A
0
+100.00%
-102,071
-100.17%
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Operating Margin
N/A
N/A
N/A
N/A
-2,154.05%
-23.36%
-2,810.54%
N/A
Return on Assets
-43.36%
-7.37%
-46.81%
-47.23%
-88.71%
+166.89%
-33.24%
N/A
Return on Equity
-46.39%
-7.02%
-49.89%
-51.46%
-102.79%
+187.63%
-35.74%
N/A
Revenue Growth
N/A
N/A
N/A
N/A
112.69%
N/A
N/A
N/A
Current Ratio
8.52
-76.07%
35.62
+830.41%
3.83
-67.56%
11.80
N/A
Cash Ratio
8.23
-76.05%
34.36
+896.68%
3.45
-68.85%
11.07
N/A
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow